Uncommon epidermal growth factor receptor (EGFR) mutations reported in non–small-cell lung cancer, accounting approximately 10%-15% of all EGFR mutations, are a heterogeneous group characterized by different clusters: exon 20 insertion and mutations, exon 18 mutations, and complex mutations. Although available data confirming the intrinsic resistance of exon 20 insertions to EGFR tyrosine kinase inhibitors (TKIs) of first- and second-line generation, data about exon 18 and complex mutations are suggesting the activity of EGFR TKIs. In this clinical study, we showed exon 18 and EGFR complex mutations might be considered sensitive uncommon mutations, showing interesting survival results.
|Titolo:||Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||01.01 - Articolo su rivista|